Sidewinder secures $137M to advance ‘precision’ ADCs
BioPharma Dive
Backed by OrbiMed, Novartis venture arm and many other investors, the biotech is among those working on newer technology that could broaden the reach of antibody-drug conjugates.
pharminent
April 8, 2026 (Last updated: April 9, 2026)
BioPharma Dive
Backed by OrbiMed, Novartis venture arm and many other investors, the biotech is among those working on newer technology that could broaden the reach of antibody-drug conjugates.
